Can medical retail lift FCPT’s returns? Inside its $4.7m deal for a Baptist Health site in Alabama
FCPT buys a Baptist Health property for $4.7M in Alabama. Find out why this healthcare deal could reshape its portfolio in 2025.
Why Meta’s purchase of Limitless could reshape how you use AI wearables every day
Meta acquires AI wearables startup Limitless to accelerate its shift toward consumer AI devices. Find out how this move shapes the future of ambient intelligence.
Is Chevron preparing a major offshore comeback in Nigeria with its 2026 rig plan
Chevron confirms 2025 bid in Nigeria’s upstream round and plans rig deployment in 2026. Find out why this signals a renewed deepwater push in West Africa.
Is Diamond Estates finally unlocking value from the Perigon acquisition? A closer look at the latest share issuance
Diamond Estates issues new shares tied to Perigon acquisition. Find out what this signals for its retail growth strategy and investor outlook.
Why Rocket Doctor AI’s interim CFO appointment could reshape its financial growth strategy
Rocket Doctor AI appoints Christopher Cherry as interim CFO and grants 1.5M equity units. Find out what this means for the firm’s growth and financial direction.
Can new CEO Ryan Batros steer Fidelity Minerals toward a copper-gold breakthrough in Peru?
Fidelity Minerals appoints new CEO Ryan Batros and completes C$1.5 million funding to scale its copper-gold exploration in Peru. Read the full update.
GSK walks away from IDEAYA cancer assets: What went wrong with synthetic lethality?
GSK ends its partnership with IDEAYA on two oncology assets. Find out what this means for IDEAYA’s pipeline, stock sentiment, and future partnerships.
From nuclear to gas and geothermal: Constellation’s Calpine buyout clears DOJ with asset divestitures
Constellation Energy’s DOJ deal clears way for Calpine acquisition. Find out what it means for U.S. power markets and investor sentiment.
Johnson & Johnson fortifies urologic oncology pipeline with compelling Inlexzo results
Johnson & Johnson's new data show Inlexzo delivers strong one-year disease-free survival. Find out how it could shift bladder cancer care.
What KT‑621 success could mean for oral immunology drugs and Kymera Therapeutics
Get ready for Kymera Therapeutics' KT‑621 Phase 1b data on December 8. Can this oral eczema drug change the future of immunology?